NOV 26, 2019 2:29 PM PST

The Immune System's Hand in Toxic Shock

WRITTEN BY: Kara Marker

While rare, toxic shock is a dangerous condition that acts fast and can be fatal. A new study identified a new target for treating toxic shock, a component of the body’s own immune system.

“Mucosal-associated invariant T cells” or “MAIT” cells are associated with a variety of infectious and non-infectious diseases. This includes toxic shock, where MAIT cells are present from the very beginning, researchers found.

Toxic shock can be derived from either Staphylococcus aureus or group A streptococcal bacteria. Toxic shock derived from group A streptococcal bacteria often stems from bacteremia, flesh-eating disease, and bacterial skin infections, while toxic shock derived from Staphylococcus aureus is usually associated with localized infection.

The present study investigated the streptococcal form of the condition, which is also responsible for common “strep throat” infections.

Common signs and symptoms of toxic shock derived from either source consist of flu-like symptoms, rash, low blood pressure, and - eventually - sepsis and organ dysfunction. Toxic shock is often associated with the misuse of tampons, but it can also develop as a result of complications from soft tissue and post-surgical infections, burns, and retained foreign bodies.

Toxic shock is rare; incidence of toxic shock in the United States is only 0.8 to 3.4 cases per 100,000 people. However, when toxic shock does occur, the consequences are grave. Toxic shock is associated with a high mortality rate and serious tissue damage. Treatment for toxic shock consists of “aggressive intravenous fluid hydration,” infection management, and removal of bacterial sources.

Toxic shock ensues when bacteria produce toxins known as superantigens and cause an inflammatory immune response, including the over-activation of cytokines. The new study found that group A streptococci trigger MAIT cells to mass-produce cytokines, resulting in a “cytokine storm.” This storm is largely responsible for the key attributes of toxic shock, including blood vessel leakage, low blood pressure, and organ failure.

A 2017 study of toxic shock derived from Staphylococcus aureus identified MAIT cells making an “unexpectedly large contribution” to the inflammatory immune response triggered by superantigens. Researchers also found that after activation by the bacterial cells, the MAIT cells no longer responded to bacterial antigens.

Researchers from the present study are excited about the possibility to use new knowledge of MAIT cells’ involvement in streptococcal toxic shock to improve care for people developing the illness. “Early diagnosis and treatment is critical for the outcome of the infection,” explained last author Anna Norrby-Teglund.

Sources: Karolinska Institutet, PNAS, “Toxic Shock Syndrome”, Nature Immunology

About the Author
  • I am a scientific journalist and enthusiast, especially in the realm of biomedicine. I am passionate about conveying the truth in scientific phenomena and subsequently improving health and public awareness. Sometimes scientific research needs a translator to effectively communicate the scientific jargon present in significant findings. I plan to be that translating communicator, and I hope to decrease the spread of misrepresented scientific phenomena! Check out my science blog: ScienceKara.com.
You May Also Like
JUN 14, 2020
Microbiology
Amping Up Immunity to Respiratory Viruses by Targeting Memory T Cells in the Lungs
JUN 14, 2020
Amping Up Immunity to Respiratory Viruses by Targeting Memory T Cells in the Lungs
It's easier than thought to activate immune cells that reside in the lungs and are involved in long-term immunity. Image ...
JUL 13, 2020
Genetics & Genomics
New Therapeutic Targets For Lupus Are Identified
JUL 13, 2020
New Therapeutic Targets For Lupus Are Identified
Advances in computational and genetic technologies have enabled scientists to search the genome to look for places where ...
JUL 17, 2020
Immunology
More Potential Antibody Therapies for COVID Emerge
JUL 17, 2020
More Potential Antibody Therapies for COVID Emerge
When it comes to clinical countermeasures against COVID-19, one class of molecules stands out among the others: antibodi ...
JUL 17, 2020
Drug Discovery & Development
Could Low-Dose Radiation Therapy Treat COVID-19?
JUL 17, 2020
Could Low-Dose Radiation Therapy Treat COVID-19?
Research from a century ago points towards the potential of low-dose radiation therapy (LDRT) for treating pneumonia. Ev ...
AUG 24, 2020
Immunology
Injectable Drug Stops HIV From Entering Cells
AUG 24, 2020
Injectable Drug Stops HIV From Entering Cells
Once in the body, HIV tracks down T cells that bear the CD4 receptor. It attaches to these immune cells, fusing itself w ...
SEP 20, 2020
Drug Discovery & Development
New Drug Combo Prolongs Survival with Advanced Kidney Cancer
SEP 20, 2020
New Drug Combo Prolongs Survival with Advanced Kidney Cancer
Biopharmaceutical company Bristol-Myers Squibb has found that a new drug combination can reduce death rates among those ...
Loading Comments...